Viking Therapeutics Inc. (VKTX)
Viking Therapeutics stock jumps after ‘great' trial of weight-loss drug
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
The U.S. presidential election will be held on November 5, 2024, but there's another event that investors may want to vote on before the election. From November 3 through November 6, the Obesity Society will hold its annual meeting, ObesityWeek 2024.
This High-Flying Stock Just Became a Better Buy
It might not be too late to get in on the party.
Viking Therapeutics: Lots Of Positives
Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate VK2735 dosages and start Phase 2 trials, with Phase 3 trials for the injectable version and VK2809 NASH drug also in the pipeline. The stock has a market cap below $9 billion while larger competitors have seen stock valuations soar by multiples of these levels indicating the opportunity for Viking Therapeutics.
Viking Therapeutics: Q3 Earnings Report Loads A Barrage Of Catalysts
Viking Therapeutics shows significant clinical progress in obesity, NASH, and X-ALD, with promising Phase II and preclinical data positioning it for potential market leadership. Despite operating at a loss, Viking maintains a strong cash position to support aggressive R&D, with Q3 financials reflecting increased expenses but sufficient liquidity. Upcoming catalysts, including Phase III trials for VK2735 and oral VK2735 studies, could significantly impact Viking's market value and competitive positioning.
Viking Therapeutics' shares soar on fresh weight-loss medication hopes
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking's stock jumping on weight-loss hopes.
Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
Viking Therapeutics' stock soars 18% as data on oral weight-loss drug looms
Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings that showed enough cash on its balance sheet to fund key clinical trials.
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
Viking Therapeutics' third-quarter earnings outpace estimates. The company plans to start a mid-stage study on its obesity pill before 2024-end.
Viking Therapeutics, Inc. (VKTX) Q3 2024 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q3 2024 Earnings Conference Call October 23, 2024 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Joon Lee – Truist Annabel Samimy – Stifel Steve Seedhouse – Raymond James Roger Song – Jefferies Jay Olson – Oppenheimer Justin Zelin – BTIG Thomas Smith – Leerink Partners Yale Jen – Laidlaw & Company Hardik Parikh – JPMorgan Alex Ramsey – William Blair Operator Welcome to the Viking Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all parties are in a listen-only mode.
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics Inc. VKTX is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735.
Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?
Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.
